Patents Assigned to Merck
  • Publication number: 20190352294
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashwin U. Rao, Brian Alexander McKittrick, Matthew Lombardo, Jacqueline D. Hicks, Amy Bittner McCracken, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu, Ping Lan, John S. Debenham, Brent R. Whitehead, Jerry A. Taylor, Zhongxiang Sun, Revathi Reddy Katipally, Jonathan E. Gable, Markus K. Dahlgren, Sathesh P. Bhat
  • Publication number: 20190352429
    Abstract: An antigen-binding molecule (ABM) comprising a cognate LC/HC dimer of an antibody light chain (LC) composed of a VL and a CL antibody domain, associated to an antibody heavy chain (HC) comprising at least a VH and a CH1 antibody domain, which association is through pairing the VL and VH domains and the CL and CH domains, wherein the amino acids at the position 18 in the CL domain and at the position 26 in the CH1 domain are of opposite polarity, wherein numbering is according to the IMGT.
    Type: Application
    Filed: February 2, 2018
    Publication date: November 21, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Florian RÜKER, Maximilian BÖNISCH
  • Publication number: 20190352564
    Abstract: The present invention relates to liquid-crystalline media comprising one or more compounds of formula C as defined in claim 1, and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas (e.g. phased array antennas).
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Dagmar KLASS, Carsten FRITZSCH, Dmitry USHAKOV, Beate SCHNEIDER
  • Publication number: 20190351622
    Abstract: The present invention relates to an additive for laser-markable and/or laser-weldable polymer materials, and in particular to the use of pigments which comprise niobium-doped titanium dioxide as laser absorbing additive in polymer materials, to polymer materials which comprise a laser absorbing additive of this type and to a laser-marked or laser-welded product comprising at least one polymer material and niobium-doped titanium dioxide containing pigments as laser absorbing additive.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 21, 2019
    Applicant: Merck Patent GmbH
    Inventors: Atsuko NISHIMAGI, Kazuhisa AZUMA, Ryuta SUZUKI
  • Patent number: 10478501
    Abstract: The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: November 19, 2019
    Assignee: Merck Patent GmbH
    Inventors: Simon Goodman, Christiane Amendt, Marcus Eber
  • Patent number: 10479801
    Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R1, R2, R3 and R7 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: November 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Tao Yu, Yonglian Zhang, John A. McCauley
  • Publication number: 20190343831
    Abstract: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
    Type: Application
    Filed: March 18, 2019
    Publication date: November 14, 2019
    Applicant: Merck Patentgesellschaft
    Inventors: Andreas Bathe, Bernd Helfert, Steffen Neuenfeld, Heike Kniel, Matthias Bartels, Susanne Rudolph, Henning Bottcher
  • Publication number: 20190345389
    Abstract: Liquid-crystalline medium contains at least one compound of formula I, and at least one compound formulae ST-1 to ST-17 and the use thereof for an active-matrix display, in particular based on the VA, PSA, PA-VA, SS-VA, SA-VA, PS-VA, PALC, IPS, PS-IPS, UB-FFS, U-IPS, FFS or PS-FFS effect.
    Type: Application
    Filed: July 22, 2019
    Publication date: November 14, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Harald HIRSCHMANN, Sabine SCHOEN
  • Patent number: 10472345
    Abstract: The present invention relates to processes for the preparation of N-protected 4-((2S,5R)-5-((benzyloxy)amino)piperidine-2-carboxamido)piperidine-1-carboxylates. Such compounds have application in the preparation of beta-lactamase inhibitors such as 7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and esters, in particular, the beta lactamase inhibitor, (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also encompasses intermediates useful in the disclosed processes and methods for their preparation.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: November 12, 2019
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Aaron M. Dumas, Jeremy P. Scott, Michael Shevlin, Zhijian Liu, John Y. L. Chung, Feng Xu, Dongfang Meng
  • Patent number: 10472347
    Abstract: Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: November 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rongze Kuang, Pauline Ting, Amjad Ali, Heping Wu, Michael Berlin, Andrew Stamford, Hongwu Wang, Gang Zhou, David Kim, Qiaolin Deng, Yeon-Hee Lim, Younong Yu
  • Patent number: 10471126
    Abstract: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: November 12, 2019
    Assignee: Merck Sharp & Dohme Ltd
    Inventors: Seoju Lee, David C. Wylie, Susan V. Cannon-Carlson
  • Patent number: 10472569
    Abstract: The invention relates to a liquid-crystalline medium comprising at least one compound of the formula I, in which R1 and R2 have the meanings indicated in Claim 1, and to the use thereof in electro-optical liquid-crystal displays.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: November 12, 2019
    Assignee: Merck Patent GmbH
    Inventors: Harald Hirschmann, Volker Reiffenrath
  • Patent number: 10472344
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: November 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anthony K. Ogawa, Linda Brockunier, James Tata, Dann L. Parker, Jr., Ming Wang
  • Publication number: 20190337918
    Abstract: Compounds of general formula (Ia), compounds of general formula (Ia?), compounds of general formula (Ib), compounds of general formula (Ib?), compounds of general formula (I), compounds of general formula (I?), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, R6, R8, R9, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds of the disclosure.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael D. Altman, Brandon D. Cash, Wonsuk Chang, Jared N. Cumming, Andrew M. Haidle, Timothy J. Henderson, James P. Jewell, Matthew A. Larsen, Rui Liang, Jongwon Lim, Min Lu, Ryan D. Otte, Tony Siu, Benjamin Wesley Trotter, Sriram Tyagarajan
  • Publication number: 20190337961
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: December 15, 2017
    Publication date: November 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio, Yan Guo, Dong Xiao
  • Publication number: 20190336685
    Abstract: A reloadable auto injector wherein a syringe assembly is movably positioned between a first position in which the needle is accommodated inside a housing and a second position in which the needle protrudes outside the housing. The assembly comprises a syringe, a plunger rod and a plunger rod driver configured to apply a force to the plunger rod to advance the plunger rod in the syringe for delivering at least one dose of medicament. A syringe driver is configured to apply a force to the assembly thereby moving the assembly from the first position to the second position. A reload handle may be connected to the assembly so that user operation of the reload handle retracts the assembly to the first position and simultaneously reload the syringe driver to thereby ready the auto injector for delivering a further dose of medicament. The plunger rod driver is not re-activated.
    Type: Application
    Filed: May 15, 2019
    Publication date: November 7, 2019
    Applicant: Merck Patent GmbH
    Inventors: Soeren BECHMANN, Flemming MADSEN, Esben W. JOHANSEN
  • Publication number: 20190336495
    Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sydney O. Ugwu, Vinay Radhakrishnan, Peter M. Ihnat, Leonore C. Witchey-Lakshmanan
  • Publication number: 20190337862
    Abstract: The invention relates to ceramic colors comprising effect pigments and a silicon comprising polymer for decoration of metallic, ceramic and glassy articles and to a process for the preparation of a ceramic glaze.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 7, 2019
    Applicant: Merck Patent GmbH
    Inventors: Lukas HAMM, Carsten HANDROSCH, Marc HUNGER, Jens KERSTEN, Cairon PLATZER, Markus THONG, Khwan Khung LIM
  • Publication number: 20190338134
    Abstract: Ceramic colours containing effect pigments and a liquid glass forming component for decoration of metallic, ceramic and glassy articles and a process for the preparation of a ceramic glaze.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 7, 2019
    Applicant: Merck Patent GmbH
    Inventors: Lukas Hamm, Carsten Handrosch, Marc Hunger, Jens Kersten, Cairon Platzer, Markus Thong, Khwan Khung Lim
  • Publication number: 20190338135
    Abstract: The invention relates to ceramic colours comprising effect pigments and a sol-gel based glassy matrix for decoration of metallic, ceramic and glassy articles and to a process for the preparation of a ceramic glaze.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 7, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Lukas HAMM, Carsten HANDROSCH, Marc HUNGER, Jens KERSTEN, Cairon PLATZER, Markus THONG, Khwan Khung LIM